Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma (Q47685069)

4 February 2018

title

Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma (English)

1 reference

4 February 2018

0 references

Hiroshi Kobayashi

1

1 reference

4 February 2018

Tomotake Okuma

2

1 reference

4 February 2018

Hiroyuki Oka

3

1 reference

4 February 2018

Toshihide Hirai

4

1 reference

4 February 2018

Takahiro Ohki

5

1 reference

4 February 2018

Masachika Ikegami

6

1 reference

4 February 2018

Ryoko Sawada

7

1 reference

4 February 2018

Yusuke Shinoda

8

1 reference

4 February 2018

Toru Akiyama

9

1 reference

4 February 2018

Kenji Sato

10

1 reference

4 February 2018

Satoshi Abe

11

1 reference

4 February 2018

Hirotaka Kawano

12

1 reference

4 February 2018

Takahiro Goto

13

1 reference

4 February 2018

Sakae Tanaka

14

1 reference

4 February 2018

publication date

31 October 2017

1 reference

4 February 2018

International Journal of Clinical Oncology

published in

1 reference

4 February 2018

Soft-tissue sarcomas in adults

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

The role of margins in extremity soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Systemic inflammation, nutritional status and survival in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Antimetastatic effects associated with platelet reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-017-1199-6

Effects of natural human interleukin-6 on thrombopoiesis and tumor progression in tumor-bearing mice

21 January 2018

1 reference

12 December 2020

Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer

1 reference

12 December 2020

Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer

1 reference

12 December 2020

Lysis of tumor cells by natural killer cells in mice is impeded by platelets

1 reference

12 December 2020

Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy

1 reference

12 December 2020

10.1007/S10147-017-1199-6

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018